医学
血糖性
背景(考古学)
北京
家庭医学
定性研究
糖尿病
焦点小组
中国
梅德林
营销
法学
政治学
古生物学
业务
社会学
内分泌学
生物
社会科学
作者
Hui Zheng,Karine Toupin‐April,Yi An,Siyao He,Ronald J. Sigal,Doug Coyle,George A. Wells,Guangwei Li
标识
DOI:10.1016/j.diabres.2020.108471
摘要
Aims This study explored decisional needs of patients with type 2 diabetes in China when considering treatment intensification to achieve good glycemic control, from both the patient’s and practitioners’ perspectives. Methods Interviews were conducted with 35 patients, and individual interviews and focus groups with 28 practitioners in Beijing, China. Topic guides based on the Ottawa Decisional Support Framework were modified for the Chinese context. Two interviewers independently extracted and coded transcripts of their notes into-overarching themes. Content analysis was performed to analyze participants’ responses. Results Patients (34/35) reported having tried different medications and some (15/35) visited multiple hospitals and consulted different doctors. Patients’ knowledge of medications was suboptimal (26/35), and most patients were not aware of their glucose levels (23/35). Although most were receptive to add-on medications, both patients and practitioners reported a range of uncertainty about the decision, and patients wanted more reliable information. Patients (15/35) and practitioners (19/28) recognized the importance of a trusting relationship when adding medications. Both reported similar values and preferences, but these were rarely discussed when adding medications. Although most patients (32/35) reported that they were capable of making a decision on adding medications, few practitioners (6/28) perceived their patients were capable. Conclusions Findings suggest a need for reliable information, more discussion about values and preferences and decision support to help engage patients and practitioners in a shared decision-making process. Decision support tools may facilitate the process for patients with type 2 diabetes in China considering add-on medications.
科研通智能强力驱动
Strongly Powered by AbleSci AI